Pharmacologic smoking cessation interventions for patients with cardiovascular conditions: a review of the safety and guidelines
CADTH
Record ID 32012000678
English
Authors' recommendations:
The efficacy of bupropion, varenicline, and NRT in patients with cardiovascular disease (CVD) has been assessed in well-conducted RCTs and systematic reviews. However, the majority of these studies were not specifically designed to fully assess the safety of smoking cessation pharmacotherapy. There were no head-to-head trials or indirect comparisons of different active treatments for smoking cessation. Overall, there is uncertainty regarding the comparative safety of varenicline, bupropion, and NRT in patients with various forms of CVD.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf/htis/may-2012/RC0352%20Smoking%20Cessation%20Cardio%20Final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Smoking Cessation
- Cardiovascular Diseases
- Bupropion
- Nicotinic Agonists
- Benzazepines
- Quinoxalines
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.